The 2018 HHS Data Strategy focuses on improving the Department’s capacity to develop statistical evidence to support policymaking and program evaluation over the next six to eight years.
Office of Science and Data Policy (SDP)
The Office of Science and Data Policy is the departmental focal point for policy research, analysis, evaluation, and coordination of department-wide public health science policy and data policy activities and issues. The Office provides authoritative advice and analytical support to the ASPE and departmental leadership on public health science policy and data policy issues and initiatives, coordinates science and data policy issues of interagency scope within HHS, and manages interagency initiatives in science policy and data policy. The Office works closely with staff from across the Department on strategic plan development and implementation efforts. The Offices also carries out a program of policy research, analysis, evaluation, and data development in these issues.
The Office of Science and Data Policy includes several components:
- Division of Science and Public Health Policy
- Division of Evidence, Evaluation and Data Policy
- Division of Strategic Planning
Topic Areas:
- HHS Data Council
- Regulatory Impact Analysis
- Strategic Planning
- Information Quality Guidelines
- Prevention and wellness
- Public health systems and functions
- Food safety and nutrition
- Drugs and devices
- Tobacco control and prevention
- Biomedical research and development
- Economic analysis
- Emergency preparedness, response, and recovery
- Data and statistical policy
- Health disparities and vulnerable populations
- Health information technology
- Microsimulation
- Privacy policy
Reports
Displaying 91 - 100 of 183. 10 per page. Page 10.
Advanced SearchUsing Evidence to Drive Decision-Making in Government
This report presents the findings from the Policy Analysis and Decision-Making Capacity project, funded by the Office of Science and Data Policy within the Office of the Assistant Secretary for Planning and Evaluation at the U.S. Department of Health and Human Services.
Economic Incentives for the Development of Rapid Point-of-Care (POC) Diagnostic Devices for C.Difficile, Carbapenem-Resistant Enterobacteriaceae (CRE), and Neisseria Gonorrhoeae
Antibacterial resistance is responsible for excess morbidity, mortality, and medical costs around the globe. Estimates vary widely, but the economic cost of antibacterial resistance in the United States could be as high as $20 billion and $35 billion a year in excess direct healthcare costs and lost productivity costs, respectively. CDC’s most recent report on U.S.
Examining Consumer Responses to Calorie Information on Restaurant Menus in a Discrete Choice Experiment
The 2014 U.S. Food and Drug Administration (FDA) final rule, “Food Labeling: Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments,” requires information on the calorie content of food items to be clearly displayed on menus.
Costs and Benefits of Selected Policy Tools to Promote Drug Development
The development of new drugs and biologics is critical to ensuring that the U.S. population continues to enjoy improvements in quality and length of life.
Estimating Medical Costs for Regulatory Benefit-Cost Analysis: Conceptual Framework and Best Practices
The U.S. Department of Health and Human Services (HHS) is required to assess the benefits and costs of its major regulations prior to promulgation. To support these assessments, in 2016 HHS issued its Guidelines for Regulatory Impact Analyses, developed under the leadership of its Office of the Assistant Secretary for Planning and Evaluation and its Department-wide Analytics Team.
Valuing Time in U.S. Department of Health and Human Services Regulatory Impact Analyses: Conceptual Framework and Best Practices
Executive Order 12866, as supplemented by Executive Orders 13563 and 13771, requires that most U.S. government agencies assess the costs, benefits, and other impacts of their major regulations before they are promulgated. Under the leadership of its Office of the Assistant Secretary for Planning and Evaluation, the U.S.
Analysis Report: Understanding the Role of Partnerships in Medical Product Development
Partnerships involving public sector organizations, academia, non-profits, and pharmaceutical companies have demonstrated their potential for addressing unmet needs in medical product research and development (R&D). Effective partnerships can enhance access to innovation, reduce risk, manage costs, and may provide a means for steering R&D investment to address societal objectives.
Final Report Volume I: Background Paper, Declining Response Rates in Federal Surveys: Trends and Implications
Over the last decade, survey response rates have been steadily declining, and this decline has raised concerns across the federal government regarding the quality and utility of national survey data.
Measurement of Interoperable Electronic Health Care Records Utilization
The objective of this project was to develop methods to measure the degree of interoperability as a result of data sharing and use between users of certified technologies who are eligible for Meaningful Use (MU) incentives and non-incentivized Trading Partners (TPs) using non-certified technologies.